BMFITT.com · Research Statistics · February 2026 Edition
150+ AI Longevity Prediction Statistics for 2026
Every stat cite-ready, source-verified, and grouped by category. Updated February 2026. Free to reference with attribution to BMFITT.com.
$740B+
Global Longevity Market 2026
|
$1.033T
AI Healthcare Market by 2034
|
$4.5B
AI Biotech VC Funding (2023)
|
40+
Primary Sources
How to cite this page: BMFITT.com, “150+ AI Longevity Prediction Statistics 2026,” February 2026 — bmfitt.com. Original primary sources are listed with every statistic below. Press inquiries: editorial@bmfitt.com
Jump to Category
💰 1. Market Size & Growth Statistics
14 statistics · Longevity economy · AI healthcare · Venture funding
$740B+
Global longevity market size projected for 2026
Research and Markets, Feb 2026
$39.34B
Global AI in healthcare market size in 2025
Fortune Business Insights, 2025
$56.01B
Projected global AI in healthcare market for 2026
Fortune Business Insights, 2025
$1.033T
Projected global AI in healthcare market by 2034
Fortune Business Insights, 2025
43.96%
CAGR for AI in healthcare from 2026 to 2034
Fortune Business Insights, 2025
44.50%
North America’s share of the global AI healthcare market in 2025
Fortune Business Insights, 2025
1 in 5
ChatGPT users who ask a health-related query at least once per week
Bessemer Venture Partners, 2026
40M+
Daily ChatGPT users asking health-related questions in 2026
Bessemer Venture Partners, 2026
Market Size & Longevity Baseline — Key Data Table
| Metric | Statistic | Source |
|---|---|---|
| Global longevity market (2026) | $740B+ | Research and Markets, Feb 2026 |
| AI in healthcare market (2025) | $39.34 billion | Fortune Business Insights, 2025 |
| AI in healthcare market (2026) | $56.01 billion | Fortune Business Insights, 2025 |
| AI in healthcare market by 2034 | $1.033 trillion | Fortune Business Insights, 2025 |
| AI healthcare CAGR (2026–2034) | 43.96% | Fortune Business Insights, 2025 |
| North America AI healthcare market share (2025) | 44.50% | Fortune Business Insights, 2025 |
| AI-driven biotech VC funding (2023) | $4.5 billion | PMC/NIH Systematic Review, 2025 |
| Hong Kong average life expectancy (highest in world, 2025) | 85 years | Insilico Medicine / Drug Discovery Online, 2025 |
| United States average life expectancy | 80 years | Insilico Medicine / Drug Discovery Online, 2025 |
| China average life expectancy | 78 years | Insilico Medicine / Drug Discovery Online, 2025 |
| Maximum verified human lifespan (Jeanne Calment, France) | 122.45 years | Nature Ageing / Bank of America Research, 2025 |
| Daily ChatGPT users asking health-related questions (2026) | 40 million+ | Bessemer Venture Partners, State of Health AI 2026 |
| ChatGPT users asking health query weekly | 1 in 5 | Bessemer Venture Partners, State of Health AI 2026 |
| Period of aggressive AI adoption in healthcare admin workflows | 18–24 months through 2026 | Bessemer Venture Partners, State of Health AI 2026 |
🎯 2. AI Model Accuracy Statistics
16 statistics · Life2vec · Gradient boosting · Epigenetic prediction benchmarks
78%
Life2vec mortality prediction accuracy over a 4-year window — #1 ranked model for individual lifespan prediction, trained on 6 million Danish citizens.
Source: Nature Computational Science, January 2024
AI Longevity Model Rankings
| Rank | Model | Accuracy / Metric | Best Application | Source |
|---|---|---|---|---|
| #1 | life2vec (Transformer) | 78% mortality accuracy (4-yr) | Individual lifespan from life events | Nature Computational Science, Jan 2024 |
| #2 | Gradient Boosting (UPenn) | R²=0.967 biological age | Clinical biological age from health data | JMIR Aging, Apr 2025 |
| #3 | GP-age (Hebrew Univ.) | ~2 years accuracy, 30 CpGs | Blood-based epigenetic age | Cell Reports Methods, 2023 |
| #4 | Horvath Epigenetic Clock | r=0.96 Pearson correlation | Cross-tissue epigenetic age | Horvath 2013 original publication |
| #5 | XAI-AGE (Deep Neural) | Outperforms 1st-gen clocks | Explainable epigenetic age prediction | Scientific Reports, 2024 |
| #6 | NCAE-CombClock | AUROC 0.953–0.972 | Youth developmental age classification | Frontiers in Aging, Dec 2024 |
| #7 | GPT-4b micro (OpenAI) | 50× Yamanaka factor improvement | Protein engineering for rejuvenation | MIT Technology Review, Jan 2025 |
AI Model Type Comparison
| Model Type | Top Accuracy | Data Required | Training Scale | Best Commercial Use |
|---|---|---|---|---|
| Transformer (life2vec) | 78% mortality (4-yr) | Life-event registry sequences | 6M+ individuals | Population research; insurance actuarial |
| Gradient Boosting (XGBoost) | R²=0.967 bio-age | Clinical health panel (16–20 markers) | Thousands of patients | Clinical diagnostics; health insurance |
| Deep Neural (AltumAge, GP-age) | ~2 years accuracy | DNA methylation arrays | 10,000+ methylomes | Biological age testing; pharma R&D |
| Large Language (GPT-4b micro) | 50× protein function | Protein sequence data | Millions of sequences | Drug discovery; cellular reprogramming |
| Convolutional (imaging-based) | AUROC 0.90+ | Medical imaging: MRI, ECG, retinal | Large clinical image datasets | Preventive diagnostics; radiology AI |
6M
Danish citizens in life2vec training dataset (2008–2016)
Nature Computational Science, 2024
R²=0.967
Gradient boosting biological age model from 16-marker health panel
JMIR Aging, UPenn, Apr 2025
50×
Improvement in Yamanaka reprogramming efficiency by OpenAI GPT-4b micro
MIT Technology Review, Jan 2025
10–20 yrs
Potential gap between chronological and biological age
Aging and Disease review, Dec 2025
🧬 3. Epigenetic Clock Statistics
12 statistics · DNA methylation · CpG site efficiency · Four generations of clock technology
Four Generations of Epigenetic Clock Technology
| Generation | Example Models | Key Innovation | Best Accuracy |
|---|---|---|---|
| 1st Gen (2011–2015) | Horvath 2013, Hannum 2013 | CpG-based chronological age from linear regression | r=0.96 Pearson correlation |
| 2nd Gen (2016–2019) | PhenoAge (Levine), GrimAge | Incorporates mortality risk, not just chronological age | Predicts all-cause mortality risk |
| 3rd Gen (2020–2023) | AltumAge, GP-age | Deep neural networks; multi-tissue; non-linear patterns | ~2 years median accuracy |
| 4th Gen (2024–2026) | DamAge/AdaptAge, NCAE-CombClock, XAI-AGE | Causal vs. correlative distinction; explainable AI | AUROC 0.953–0.972; first causal clock |
353
CpG sites in Horvath’s 2013 pan-tissue epigenetic clock — the original benchmark
Horvath 2013
30
CpG sites used by GP-age to achieve ~2-year accuracy — outperforms models using 10× more sites
Cell Reports Methods, Hebrew Univ. 2023
142
Publicly available datasets used to train AltumAge deep neural network across multiple tissue types
npj Aging
4,651
Individuals in Framingham Heart Study cohort used to validate DamAge and AdaptAge clocks
Nature Aging, Brigham & Women’s, Feb 2024
Epigenetic Clock — Key Data Table
| Metric | Statistic | Source |
|---|---|---|
| Average error of world’s first epigenetic clock (UCLA, 2011) | 5.2 years (from saliva) | UCLA, 2011 |
| Proportion of human genome with age-related DNA methylation changes | ~28% | PMC, Aging and Disease, 2025 |
| Year first causal epigenetic clocks (DamAge/AdaptAge) published | 2024 | Brigham and Women’s Hospital, Nature Aging, Feb 2024 |
| Status of DNA methylation clocks for biological age estimation | Gold Standard (confirmed Dec 2025) | Aging and Disease systematic review, Dec 2025 |
💊 4. AI Drug Discovery Statistics
18 statistics · Timelines · Costs · Clinical milestones · Industry benchmarks
>90%
Failure rate of traditional clinical drug development — the core problem AI drug discovery directly addresses by reducing cost, time, and trial-and-error cycles.
Source: Bank of America Breakthrough Technology Research, 2025
4–6 yrs
Conventional time: drug target ID to clinical candidate
PMC/NIH Systematic Review, 2025
<18 mo
Insilico Medicine: TNIK target ID to Phase 2a clinical trial candidate
PMC/NIH Systematic Review, 2025
~$150K
Cost of Insilico’s TNIK inhibitor discovery vs. hundreds of millions conventionally
PMC/NIH Systematic Review, 2025
$2.1B+
Value of Insilico Medicine’s pipeline out-licensing agreements (2025)
BioSpace, 2025
Top AI Drug Discovery Companies — Rankings 2026
| Rank | Company | Key AI Platform | Stage / Milestone | Funding |
|---|---|---|---|---|
| #1 | Insilico Medicine | Pharma.AI generative platform | Phase 2 trials; $293M HK IPO (2025) | $2.1B+ out-licensing |
| #2 | Altos Labs (Bezos) | Yamanaka factor reprogramming | Entering human clinical trials 2026 | $3B raised |
| #3 | Retro Biosciences | GPT-4b micro protein engineering | 50× Yamanaka improvement | $180M (Sam Altman) |
| #4 | Recursion Pharmaceuticals | Phenomics + deep learning | Merged with Exscientia 2024 | Public (RXRX) |
| #5 | Isomorphic Labs (Google) | AlphaFold-derived platform | Early-stage drug programmes | DeepMind spinout |
| #6 | Gero (Roche/Chugai) | AI aging biomarker targets | $1B+ potential deal with Chugai | Partnership-funded |
| #7 | NewLimit (Coinbase CEO) | Epigenetic mRNA reprogramming | Phase 1 liver disease candidate | $130M Series B 2025 |
AI Drug Discovery — Additional Key Stats
| Metric | Statistic | Source |
|---|---|---|
| Time compression vs. conventional drug discovery | 95%+ (18 months vs. 4–6 years) | BMFITT.com calculation from PMC/NIH 2025 data |
| Insilico Medicine Hong Kong IPO raise | ~$293 million | The Longevity Initiative, January 2026 |
| Active AI drug discovery projects at Insilico | 30 | Fortune, October 2025 |
| Sanofi–Exscientia AI drug discovery partnership value | $1.2 billion | PMC/NIH Systematic Review, 2025 |
| Gero–Chugai (Roche) AI aging biomarker partnership potential | $1B+ if drugs reach market | The Longevity Initiative, January 2026 |
| Higher cancer detection rate — RadNet AI mammography vs. standard | 43% | Bessemer Venture Partners, State of Health AI 2026 |
| Women in RadNet’s landmark AI mammography study | 747,604 | Bessemer Venture Partners, State of Health AI 2026 |
| More likely women are to have cancer detected with AI mammography | 21% | Bessemer Venture Partners, State of Health AI 2026 |
📈 5. Company Funding & Valuation Statistics
12 statistics · All figures verified via CB Insights October 2025 and company announcements
$3B
Altos Labs total funding — Jeff Bezos-backed cellular reprogramming
CB Insights, October 2025
$1.8B
Neko Health valuation at January 2025 Series B
CB Insights, October 2025
$293M
Insilico Medicine HK IPO — largest biotech IPO in Hong Kong (2025)
The Longevity Initiative, Jan 2026
$260M
Neko Health Series B funding raised — January 2025
CB Insights, October 2025
$180M
Retro Biosciences total funding — Sam Altman-backed, OpenAI collaborator
CB Insights, October 2025
$130M
NewLimit (Brian Armstrong) Series B — epigenetic mRNA reprogramming (2025)
CB Insights, October 2025
$110M
Insilico Medicine Series E financing round
BioSpace, 2025
$4.5B
Total AI-driven biotech VC funding globally — 2023 baseline before 2024–25 acceleration
PMC/NIH Systematic Review, 2025
🏥 6. Commercial Longevity Platform Statistics
12 statistics · Consumer adoption · Pricing · Revenue · Patient numbers
Top Commercial Longevity Platforms 2026
| Platform | AI Application | Key Metric (2025–2026) | Price Point |
|---|---|---|---|
| Neko Health | Full-body AI health prediction + trajectory modelling | $1.8B valuation; 100K+ waitlist | Subscription-based |
| Prenuvo | Whole-body MRI + AI anomaly detection | 130,000+ scans (May 2025) | $3,999 per scan |
| Function Health / Ezra | Lab testing + whole-body MRI (merged May 2025) | Consolidated preventive platform | Tiered subscription |
| Fountain Life | Genomic + biomarker + AI coaching | Multi-tier longevity programmes | $3,000–$25,000+/yr |
| Midi Health | AI-powered women’s longevity + menopause | $150M revenue run rate (2025 proj.) | Telehealth subscription |
$150M
Midi Health projected 2025 revenue run rate
CB Insights, October 2025
$60M
Midi Health 2024 revenue (grew ~150% to $150M projected run rate)
CB Insights, October 2025
$3,999
Prenuvo whole-body MRI scan with AI anomaly detection (per scan)
Prenuvo verified pricing, 2025
$499/yr
Function Health annual comprehensive biomarker panel cost
Function Health verified pricing, 2025
100,000+
Patients on Neko Health’s waitlist (Sweden & UK, 2025)
CB Insights / Neko Health, 2025
70
Sensors in a single Neko Health full-body scan for biological age assessment
CB Insights / Neko Health, 2025
130,000+
Whole-body MRI scans completed by Prenuvo as of May 2025
CB Insights, October 2025
⌚ 7. Wearables & Biometric Data Statistics
10 statistics · Real-time longevity signals · Device capabilities · Regulatory status
Wearable Biomarkers & AI Longevity Signal Strength
| Biomarker | Wearable Source | AI Longevity Signal | Clinical Validation |
|---|---|---|---|
| Heart Rate Variability (HRV) | Oura, Apple Watch, WHOOP | Autonomic nervous system ageing; stress | Strong — peer-reviewed evidence |
| Sleep architecture | Oura Ring, WHOOP | REM/deep sleep ratio predicts cognitive ageing | Growing evidence base |
| Blood oxygen (SpO2) | Apple Watch, Fitbit | Cardiorespiratory fitness; hypoxia risk | Clinically validated |
| Skin temperature | Oura Ring | Metabolic and immune status | Moderate evidence |
| Activity / VO2max estimate | Apple Watch, Garmin | Cardiovascular biological age | Strong — FDA-cleared |
| ECG-based biological age | Apple Watch | AI-derived biological age from ECG trace | Strong ECG-age association |
| Blood pressure (emerging) | WHOOP, Samsung | Cardiovascular risk trajectory | Under FDA review 2025–2026 |
#1 Layer
Wearable technology is the primary real-time data input for AI biological age models in 2026
Research and Markets, Longevity Market Report 2026
FDA-Cleared
VO2max estimation from Apple Watch and Garmin — only wearable longevity metric with FDA clearance (2025)
FDA / Apple verified, 2025
Jan 2026
OpenAI acquired healthcare startup Torch, integrating medical memory into ChatGPT Health
OpenAI / Bessemer Venture Partners Health AI 2026
2028
Projected year regulatory boundary between wearable wellness coaching and clinical AI diagnosis is formally defined
Healthcarehuddle.com 2026 Landscape Report
⚖️ 8. Ethics & Regulation Statistics
10 statistics · Regulatory frameworks · Documented harm risks · Privacy constraints
0
Jurisdictions worldwide with a specific regulatory framework governing AI longevity predictions in insurance pricing — as of February 2026.
Source: BMFITT.com regulatory landscape synthesis, Feb 2026
4 Harms
Direct harm categories from AI death prediction tools: insurance denial, discriminatory hiring, treatment deprioritisation, altered loan terms
THODEX Research, December 2024
GDPR
EU regulation that effectively blocked commercial deployment of life2vec for individual predictions — registry data cannot be shared under EU privacy law
George Washington University Himmelfarb Library, 2024
Do Not Use
Official stance of life2vec’s own creators — model must NOT be used for predictions about real individuals, per Prof. Tina Eliassi-Rad
Life2vec.dk / Nature Computational Science, 2024
Fraudulent
Status of many third-party sites claiming to offer individual life2vec death predictions — confirmed by life2vec.dk official page
Life2vec.dk official research page, 2024
Regulation & Ethics — Key Data Table
| Metric | Statistic | Source |
|---|---|---|
| Jurisdictions with AI longevity prediction regulation in insurance | 0 (as of Feb 2026) | BMFITT.com regulatory synthesis, Feb 2026 |
| Month FDA published AI strategic roadmap endorsing in silico testing | April 2025 | FDA / Bessemer Venture Partners Health AI 2026 |
| FDA classification for AI longevity tools making clinical claims | SaMD (Software-as-a-Medical-Device) | FDA SaMD regulatory framework, 2024–2025 |
🌍 9. Global AI Longevity Research Rankings
Country-by-country breakdown · VC · Registry data · Life expectancy · Regulation
| Rank | Country | Key Strength | Leading Organisation | Life Expectancy |
|---|---|---|---|---|
| #1 | United States | VC funding; biotech ecosystem; FDA SaMD framework | Altos Labs, Retro, Recursion, Insilico (US HQ) | 80 years |
| #2 | Denmark / Scandinavia | National registry; 6M-citizen population data | DTU, Copenhagen Univ. (life2vec) | 83+ years |
| #3 | Hong Kong / China | AI infrastructure speed; clinical trial scale | Insilico Medicine HQ | 85 years (HK) |
| #4 | United Kingdom | NHS data access; academic AI excellence | Neko Health UK; NHS-AI pilots | 82 years |
| #5 | Japan | Oldest living population; deep longevity data | Government longevity research programs | 84+ years |
| #6 | Switzerland / Germany | Biotech precision; mature regulatory frameworks | Novartis, Roche, Gero (Roche partnership) | 83+ years |
📚 10. Primary Sources Referenced
40+ peer-reviewed journals, industry reports, and verified primary databases
- Nature Computational Science, January 2024 (life2vec)
- JMIR Aging, University of Pennsylvania, April 2025
- Cell Reports Methods, Hebrew University, 2023
- Fortune Business Insights, AI Healthcare Market, 2025
- Research and Markets, Longevity Market Report, Feb 2026
- CB Insights, Longevity Company Tracker, October 2025
- Bessemer Venture Partners, State of Health AI 2026
- Society of Actuaries Research Institute, 2025 Essays
- PMC/NIH Systematic Review on AI Drug Discovery, 2025
- Bank of America Breakthrough Technology Research, 2025
- MIT Technology Review, January 2025 (GPT-4b micro)
- The Longevity Initiative, January 2026 Review
- BioSpace, Insilico Medicine coverage, 2025
- Frontiers in Aging, December 2024 (NCAE-CombClock)
- Scientific Reports, 2024 (XAI-AGE neural network)
- Aging and Disease comprehensive review, December 2025
- Nature Aging, Brigham and Women’s Hospital, Feb 2024
- George Washington University Himmelfarb Library, 2024
- THODEX Research, December 2024
- TechBullion, 2026 Healthcare Predictions
- Healthcarehuddle.com, 2026 Healthcare Landscape Report
- Lifespan.io Expert Roundup, January 2026
- Aging (Albany NY) / Wilczok review, January 2025
- Life2vec.dk official research page (DTU et al.)
- npj Aging (AltumAge multi-tissue network research)
- ScienceDaily, Brigham and Women’s Hospital, 2024
- Drug Discovery Online, Zhavoronkov interview, 2025
- Scispot Longevity Biotech Analysis, 2025–2026
- FDA SaMD Framework / April 2025 AI Roadmap
- Horvath 2013 Pan-Tissue Epigenetic Clock (original pub.)
- UCLA 2011 First Epigenetic Clock Study (saliva-based)
- Framingham Heart Study (DamAge/AdaptAge validation)
- Fortune, October 2025 (Insilico pipeline)
- PMC / Aging and Disease, 2025 (genome methylation)
- OpenAI Torch acquisition / ChatGPT Health, Jan 2026
- Function Health / Ezra merger announcement, May 2025
- Neko Health Series B press release, January 2025
- NewLimit Series B announcement, 2025
- Nature Computational Science journal
- Society of Actuaries — AI Longevity Essays
Using these statistics in your article? Please link back to BMFITT.com when citing these statistics. This keeps the data current and lets your readers verify the primary sources. Use: “According to BMFITT.com’s 2026 AI Longevity Statistics Report…” — For press inquiries or custom data cuts: editorial@bmfitt.com
© 2026 BMFITT.com · Beauty, Health & Fitness Industry Intelligence · Freely distributable with attribution.
